Foundation Medicine, Flatiron Health collaborate to develop data platform
Foundation Medicine, a molecular information company based in Cambridge, Mass., and Flatiron Health, a healthcare technology company headquartered in New York, have announced a strategic collaboration to develop a unique, proprietary cloud-based information platform combining genomic and clinical treatment and outcomes data to significantly advance the field of precision medicine for cancer.
This collaboration integrates the Flatiron Health OncologyCloud platform with Foundation Medicine’s comprehensive genomic profiling capabilities to support evidence-based drug development and help accelerate the delivery of safe, effective and targeted new cancer therapies to patients.
“Flatiron Health and Foundation Medicine share a common belief that integrated clinical and molecular information can drive a revolution in how patients battling cancer can be treated,” said Nat Turner, co-founder and CEO, Flatiron Health. “Together, Foundation Medicine and Flatiron Health will bring our collective expertise in oncology, informatics and technology to develop a first-in-class platform that helps advance cancer care.”
Foundation Medicine and Flatiron Health will work together to co-develop products based on a comprehensive, HIPAA-compliant information platform that seamlessly analyzes and integrates clinical treatment and outcome data with matched comprehensive genomic profiling data for patients who have undergone testing with FoundationOne or FoundationOne Heme. Life science companies will be able to utilize this cloud-based platform to enable better selection of molecular candidates, more efficient clinical trial design and faster patient recruitment into clinical trials.
“The marriage of information analytics and cancer genomics represents one of the most powerful opportunities to redefine and reshape the way cancer drugs are developed and delivered to patients in need,” said Michael J. Pellini, M.D., president and CEO of Foundation Medicine. “The jointly developed information products born from this collaboration will provide life science companies with a powerful new tool to access actionable data that informs the development of targeted new cancer therapies.”
The proprietary products resulting from this combined genomic and clinical outcomes data asset are expected to be commercially available for licensing by life science companies beginning in mid-2015.